SG11201502503RA - Azaquinazoline carboxamide derivatives - Google Patents

Azaquinazoline carboxamide derivatives

Info

Publication number
SG11201502503RA
SG11201502503RA SG11201502503RA SG11201502503RA SG11201502503RA SG 11201502503R A SG11201502503R A SG 11201502503RA SG 11201502503R A SG11201502503R A SG 11201502503RA SG 11201502503R A SG11201502503R A SG 11201502503RA SG 11201502503R A SG11201502503R A SG 11201502503RA
Authority
SG
Singapore
Prior art keywords
carboxamide derivatives
azaquinazoline
azaquinazoline carboxamide
derivatives
carboxamide
Prior art date
Application number
SG11201502503RA
Other languages
English (en)
Inventor
Bayard R Huck
Ruoxi Lan
Justin Potnick
Lizbeth Celeste Deselm
Mark W Cronin Jr
Constantin Neagu
Xiaoling Chen
Roch Boivin
Theresa L Johnson
Andreas Goutopoulos
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SG11201502503RA publication Critical patent/SG11201502503RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D253/00Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201502503RA 2012-11-29 2013-11-27 Azaquinazoline carboxamide derivatives SG11201502503RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261731075P 2012-11-29 2012-11-29
PCT/US2013/072141 WO2014085528A1 (en) 2012-11-29 2013-11-27 Azaquinazoline carboxamide derivatives

Publications (1)

Publication Number Publication Date
SG11201502503RA true SG11201502503RA (en) 2015-04-29

Family

ID=49759613

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201502503RA SG11201502503RA (en) 2012-11-29 2013-11-27 Azaquinazoline carboxamide derivatives
SG10201800741QA SG10201800741QA (en) 2012-11-29 2013-11-27 BENZO-[d][1,2,3]TRIAZINE COMPOUNDS AND USE AS p70S6K INHIBITORS

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201800741QA SG10201800741QA (en) 2012-11-29 2013-11-27 BENZO-[d][1,2,3]TRIAZINE COMPOUNDS AND USE AS p70S6K INHIBITORS

Country Status (19)

Country Link
US (3) US9440968B2 (pt)
EP (1) EP2925747B1 (pt)
JP (1) JP6290917B2 (pt)
KR (1) KR20150090044A (pt)
CN (1) CN105793254B (pt)
AU (1) AU2013352261B2 (pt)
BR (1) BR112015011974A8 (pt)
CA (1) CA2887539C (pt)
CL (1) CL2015001187A1 (pt)
EA (2) EA033655B1 (pt)
ES (1) ES2821102T3 (pt)
IL (2) IL239054B (pt)
MX (1) MX2015006516A (pt)
NZ (1) NZ706418A (pt)
PE (1) PE20151782A1 (pt)
PH (2) PH12015500712A1 (pt)
SG (2) SG11201502503RA (pt)
UA (1) UA115154C2 (pt)
WO (1) WO2014085528A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ706418A (en) * 2012-11-29 2019-09-27 Merck Patent Gmbh Azaquinazoline carboxamide derivatives
CN108473472B (zh) 2015-10-02 2021-02-12 圣提内尔肿瘤学有限公司 作为p70s6激酶抑制剂的2-氨基喹唑啉衍生物
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
JOP20220100A1 (ar) 2019-11-01 2023-01-30 Syngenta Crop Protection Ag مركبات هتيروماتية ثنائية الحلقة مندمجة نشطة من الناحية المبيدة للآفات
CA3221180A1 (en) 2021-06-24 2022-12-29 Syngenta Crop Protection Ag 2-[3-[1 [(quinazolin-4-yl)amino]ethyl]pyrazin-2-yl]thiazole-5-carbonitrile derivatives and similar compounds as pesticides
WO2023247360A1 (en) 2022-06-21 2023-12-28 Syngenta Crop Protection Ag Pesticidally active fused bicyclic heteroaromatic compounds
CN117304182A (zh) * 2022-06-22 2023-12-29 上海海和药物研究开发股份有限公司 一类具有嘧啶并六元环结构的化合物、包含其的药物组合物及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA287539A (en) * 1929-02-26 William Hallden Karl Severing apparatus
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
EP0946554A1 (en) * 1996-11-27 1999-10-06 Pfizer Inc. Fused bicyclic pyrimidine derivatives
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
WO2004014873A1 (ja) * 2002-08-09 2004-02-19 Kyorin Pharmaceutical Co., Ltd. 4-置換キナゾリン-8-カルボン酸アミド誘導体とその薬理上許容される付加塩
EP1615906A1 (en) 2003-04-03 2006-01-18 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
CA2539339A1 (en) 2003-09-30 2005-04-14 Irm Llc Compounds and compositions as protein kinase inhibitors
CA2541989C (en) 2003-10-24 2013-10-01 Exelixis, Inc. P70s6 kinase modulators and method of use
CA2546117A1 (en) 2003-11-21 2005-06-16 Novartis Ag 1h-imidazoquinoline derivatives as protein kinase inhibitors
EP1694331B8 (en) 2003-12-09 2010-02-24 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY of the DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods for suppressing an immune response or treating a proliferating disorder
AU2005249380C1 (en) 2004-04-23 2012-09-20 Exelixis, Inc. Kinase modulators and methods of use
US7994172B2 (en) 2004-12-28 2011-08-09 Exelixis, Inc. [1H-pyrazolo[3, 4-D]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (P70s6k, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
US8343953B2 (en) 2005-06-22 2013-01-01 Astex Therapeutics Limited Pharmaceutical compounds
CA2628920C (en) 2005-11-22 2015-12-29 Kudos Pharmaceuticals Limited Pyrido-,pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
KR101115891B1 (ko) 2007-03-23 2012-02-13 에프. 호프만-라 로슈 아게 아자-피리도피리미딘온 유도체
UA99284C2 (ru) 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ
CN101230045B (zh) * 2008-02-14 2013-04-10 沈阳药科大学 芳环并三嗪类衍生物及其应用
KR101699991B1 (ko) * 2009-02-11 2017-01-26 메르크 파텐트 게엠베하 신규의 아미노 아자헤테로시클릭 카르복사미드
SG178899A1 (en) * 2009-08-28 2012-04-27 Array Biopharma Inc Raf inhibitor compounds and methods of use thereof
ES2729754T3 (es) 2010-07-29 2019-11-06 Merck Patent Gmbh Carboxamidas azaheterocíclicas de aminas cíclicas
UA110113C2 (xx) * 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди
BR112013012488B1 (pt) * 2010-11-24 2021-08-31 Merck Patent Gmbh Azetidinas quinazolina carboxamida, seus usos e seu processo de fabricação, composição farmacêutica, e kit
US8791091B2 (en) 2011-12-02 2014-07-29 Bristol-Myers Squibb Company Aryl dihydropyridinone and piperidinone MGAT2 inhibitors
NZ706418A (en) * 2012-11-29 2019-09-27 Merck Patent Gmbh Azaquinazoline carboxamide derivatives

Also Published As

Publication number Publication date
US10233160B2 (en) 2019-03-19
AU2013352261B2 (en) 2018-05-10
PH12016502534B1 (en) 2017-11-20
UA115154C2 (uk) 2017-09-25
CN105793254B (zh) 2020-10-23
IL239054A0 (en) 2015-07-30
ES2821102T3 (es) 2021-04-23
US9981925B2 (en) 2018-05-29
PH12015500712B1 (en) 2015-05-18
WO2014085528A1 (en) 2014-06-05
US20180237402A1 (en) 2018-08-23
SG10201800741QA (en) 2018-03-28
BR112015011974A8 (pt) 2019-10-08
PH12015500712A1 (en) 2015-05-18
IL256646A (en) 2018-02-28
JP6290917B2 (ja) 2018-03-07
EP2925747B1 (en) 2020-06-24
JP2016501229A (ja) 2016-01-18
AU2013352261A1 (en) 2015-04-23
CA2887539C (en) 2021-10-26
PE20151782A1 (es) 2015-12-02
EP2925747A1 (en) 2015-10-07
CN105793254A (zh) 2016-07-20
EA029144B1 (ru) 2018-02-28
US20150259339A1 (en) 2015-09-17
NZ706418A (en) 2019-09-27
US9440968B2 (en) 2016-09-13
EA033655B1 (ru) 2019-11-13
EA201792187A1 (ru) 2018-02-28
EA201500573A1 (ru) 2016-02-29
CA2887539A1 (en) 2014-06-05
US20160340323A1 (en) 2016-11-24
IL239054B (en) 2021-04-29
MX2015006516A (es) 2015-08-14
CL2015001187A1 (es) 2015-08-28
KR20150090044A (ko) 2015-08-05
BR112015011974A2 (pt) 2017-07-11
IL256646B (en) 2020-03-31
PH12016502534A1 (en) 2017-11-20

Similar Documents

Publication Publication Date Title
HUS2200040I1 (hu) Benzimidazol-prolin származékok
HK1205740A1 (en) Pyrrolotriazinone derivatives
HK1207375A1 (en) Piperidinylpyrazolopyridine derivative
HK1205508A1 (en) New bicyclicpyridine derivatives
IL236295A (en) The history of indanesulfamide
ZA201502175B (en) Oxazolidin-2-one-pyrimidine derivatives
SG11201502503RA (en) Azaquinazoline carboxamide derivatives
PT2838883T (pt) Novos derivados de fenil-tetra-hidroisoquinolina
HK1206714A1 (en) Triazole carboxamide derivatives
HK1212671A1 (zh) -氨基環戊烷甲酰胺衍生物
EP2805941A4 (en) SUBSTITUTED PHENYLAZOLE DERIVATIVE
EP2873660A4 (en) INDOLCARBOXAMIDDERIVAT
SG11201404325VA (en) Pyrimidooxazocine derivatives as mtor - inhibitors
EP2842958A4 (en) NAPHTHOBISTHIADIAZOLDERIVAT
HK1204621A1 (en) 4-alkanoylamino-3-pyrazolone derivative 4--3-